| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/02/2013 | CA2579937C Methods for antibody library screening |
| 07/02/2013 | CA2553721C Inhibition of biogenic sulfide production via biocide and metabolic inhibitor combination |
| 07/02/2013 | CA2533117C Combinations for the treatment of depression |
| 07/02/2013 | CA2521379C Pharmaceutical formulations containing methylnaltrexone |
| 07/02/2013 | CA2504582C Drug delivery device comprising a bilayered polymeric coating having an inhibitor of the mamalian target of rapamycin incorporated into the first polymeric coating layer |
| 07/02/2013 | CA2470964C Broadspectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors |
| 07/02/2013 | CA2421151C Modified vaccinia ankara virus variant |
| 07/02/2013 | CA2373178C The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders |
| 06/27/2013 | WO2013096870A1 Compositions and methods for treating amyotrophic lateral sclerosis |
| 06/27/2013 | WO2013094682A1 Local-administration-type medicinal agent for ameliorating deglutition disorder |
| 06/27/2013 | WO2013093248A1 Novel combinations containing n-hydroxy-4-(2-[3-(n, n-dimethylaminomethyl) benzofuran-2-ylcarbonylamino]ethoxy)benzamide in nasopharyngeal carcinoma |
| 06/27/2013 | WO2013092984A1 Combination of (3s,3s') 4,4'-disulfanediylbis(3-aminobutane 1-sulfonic acid) and a second antihypertensive agent |
| 06/27/2013 | WO2013092942A1 Use of aminobenzamide derivatives for controlling animal parasites |
| 06/27/2013 | WO2013092269A1 Pharmaceutical compositions comprising glitazones and nrf2 activators |
| 06/27/2013 | WO2013091897A1 Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol |
| 06/27/2013 | WO2013091144A1 Propenoate derivatives of betulin |
| 06/27/2013 | US20130165518 Ibuprofen and narcotic analgesic compositions |
| 06/27/2013 | US20130165500 RNA Interference Mediated Inhibition of Prolyl Hydroxylase Domain 2 (PHD2) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| 06/27/2013 | US20130165494 1,5-Diaryl-2-alkylpyrrole-3-Substituted Nitro Esters, Selective COX-2 Inhibitors and Nitric Oxide Donors |
| 06/27/2013 | US20130165489 Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof |
| 06/27/2013 | US20130165483 Heteroaryls and uses thereof |
| 06/27/2013 | US20130165478 Pyrazolopyridinone derivatives as lpa receptor antagonists |
| 06/27/2013 | US20130165472 Heteroaryls and uses thereof |
| 06/27/2013 | US20130165466 Polymer conjugates of opioid antagonists |
| 06/27/2013 | US20130165464 Heteroaryls and uses thereof |
| 06/27/2013 | US20130165463 Inhibition of focal adhesion kinase for control of scar tissue formation |
| 06/27/2013 | US20130165459 Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof |
| 06/27/2013 | US20130165446 Benzo-or pyrido-imidazole derivative |
| 06/27/2013 | US20130165442 Modulators of ATP-Binding Cassette Transporters |
| 06/27/2013 | US20130165439 Chemical compounds |
| 06/27/2013 | US20130165437 Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders. |
| 06/27/2013 | US20130165418 Opioid agonist/opioid antagonist/acetaminophen combinations |
| 06/27/2013 | US20130165401 Nucleoside phosphoramidates |
| 06/27/2013 | US20130165399 Therapeutic agent for inflammatory diseases, containing adenosine n1-oxide as an effective ingredient |
| 06/27/2013 | US20130165392 Hepatocyte growth factor mimics as therapeutic agents |
| 06/27/2013 | US20130165383 Apo-2 ligand/trail variants and uses thereof |
| 06/27/2013 | US20130165368 Antimicrobial compounds |
| 06/27/2013 | US20130164386 Targeting the Alpha3 Subnit of Na+-K+-ATPase for the Treatment of Cough with Sulfenamides |
| 06/27/2013 | US20130164384 Methods of treating bowel diseases by administering a bowel cleanser and an antibiotic |
| 06/27/2013 | US20130164358 Oral compositions comprising a zinc compound and an anti-microbial agent |
| 06/27/2013 | US20130164351 Methods of treating bacterial infections through pulmonary delivery of fusidic acid |
| 06/27/2013 | US20130164341 Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications |
| 06/27/2013 | US20130164338 Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder |
| 06/27/2013 | US20130164330 Methods and Compositions for Treatment of Hematologic Cancers |
| 06/27/2013 | US20130164328 Methods for enhancing immune response |
| 06/27/2013 | US20130164308 Staphylococcus aureus specific antibodies and uses thereof |
| 06/27/2013 | US20130164295 VEGF/DLL4 Binding Agents and Uses Thereof |
| 06/27/2013 | US20130164287 Soluble tumor necrosis factor receptor treatment of medical disorders |
| 06/27/2013 | US20130164282 Treatment of cancer |
| 06/27/2013 | US20130164280 Pyrazolo[1,5-a]pyrimidines as antiviral agents |
| 06/27/2013 | US20130164273 Reversibly inactivated acidified plasmin composition |
| 06/27/2013 | US20130164261 Substituted nucleotide analogs |
| 06/27/2013 | US20130164260 Antiviral compounds |
| 06/27/2013 | US20130164256 Immunobinders directed against tnf |
| 06/27/2013 | US20130164249 Compositions and methods for inhibiting viral and bacterial activity |
| 06/27/2013 | US20130164232 Substantive sunscreen formulation |
| 06/27/2013 | US20130164218 Hypoxia inducible factor-1 pathway inhibitors and uses as anticancer and imaging agents |
| 06/27/2013 | US20130164216 Bladder cancer tumor marker, antibody and use thereof |
| 06/27/2013 | DE102010014260A1 Treating e.g. cancer and multiple sclerosis in humans or animals, comprises placing patient into artificial coma, and treating tumors, abnormal cells and/or disease caused by optimized protein-free or very low-protein extreme fasting cure |
| 06/26/2013 | EP2606933A2 Combination of an IAP-inhibitor and a taxane |
| 06/26/2013 | EP2606909A1 Method and composition for treating, preventing and diagnosing cancer containing cancer stem cells or derived therefrom |
| 06/26/2013 | EP2606901A1 Neuregulin based methods and compositions for treating cardiovascular diseases |
| 06/26/2013 | EP2606890A1 Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer |
| 06/26/2013 | EP2605776A1 Diazoxide for use in the treatment of amyotrophic lateral sclerosis (als) |
| 06/26/2013 | EP2605766A2 Novel combination therapy for the treatment of cancer |
| 06/26/2013 | EP2605764A1 Combination anti - cancer therapy |
| 06/26/2013 | EP2605650A2 Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol |
| 06/26/2013 | CN103180315A Method of treatment for mental disorders |
| 06/26/2013 | CN103179974A New treatments of hepatitis c virus infection |
| 06/26/2013 | CN103179966A Vitamin e formulations of sulfamide ns3 inhibitors |
| 06/26/2013 | CN103179960A Pharmaceutical combinations for the treatment of metabolic disorders |
| 06/26/2013 | CN103173473A Asiatic corn borer beta-N-amino acetyl glucosyl hydrolase (OfOGA) gene and application thereof |
| 06/26/2013 | CN103173402A Stimulation of pancreatic beta cell proliferation |
| 06/26/2013 | CN103172819A Biodegradable polyurethane with amino on side chain and preparation method and application thereof |
| 06/26/2013 | CN103169974A Drug carrier system and preparation method thereof |
| 06/26/2013 | CN103169973A Treatment of breast cancer with iodonitrobenzamides in combination with anti-tumor agents |
| 06/26/2013 | CN103169972A New application of statin compound as topical medicine for preventing and curing osteoporotic fracture |
| 06/26/2013 | CN103169971A Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
| 06/26/2013 | CN103169970A Pharmaceutical composition for treating viral pneumonia |
| 06/26/2013 | CN103169958A Survivin peptide vaccine |
| 06/26/2013 | CN103169956A Drug for dispelling effects of alcohol and preventing anesthesia and production method thereof |
| 06/26/2013 | CN103169948A Regulation function of hepcidin regulatory protein to body immunity and application of hepcidin regulatory protein |
| 06/26/2013 | CN103169671A Preparation method of insoluble drug sustained-release granules |
| 06/26/2013 | CN103169668A Painless synergistic amoxicillin powder injection for animals and preparation method thereof |
| 06/26/2013 | CN102451249B Drug for treating burn and scald, and application thereof |
| 06/26/2013 | CN102391517B Nanometer micelle capable of intelligently releasing medicine as well as preparation method and application thereof |
| 06/26/2013 | CN102105142B Compositions for treating rosacea comprising chitosan and a dicarboxylic acid |
| 06/26/2013 | CN101983073B Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
| 06/26/2013 | CN101505788B Prophylactic and/or therapeutic agents for peripheral neuropathy |
| 06/25/2013 | US8470990 Ribosome structure and protein synthesis inhibitors |
| 06/25/2013 | US8470969 Apo-2 ligand/trail formulations |
| 06/25/2013 | US8470868 Formulation for the prevention of cardiovascular disease |
| 06/25/2013 | US8470808 Oxidant scavengers for treatment of type I diabetes or type II diabetes |
| 06/25/2013 | US8470798 Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
| 06/25/2013 | US8470775 Compositions and methods for reducing the risk of preeclampsia |
| 06/25/2013 | US8470368 Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| 06/25/2013 | US8470346 Anti-viral pharmaceutical compositions |
| 06/25/2013 | US8470343 Immunogenic compositions and uses thereof |
| 06/25/2013 | US8470342 Methods of altering an immune response induced by CpG oligodeoxynucleotides |
| 06/25/2013 | CA2692295C Combined use of methylol-transfer agents and fas-ligands in the treatment of cancer |